PT  - JOURNAL ARTICLE
AU  - Clerc, Olivier F.
AU  - Cuddy, Sarah A. M.
AU  - Jerosch-Herold, Michael
AU  - Benz, Dominik C
AU  - Katznelson, Ethan
AU  - Canseco Neri, Jocelyn
AU  - Taylor, Alexandra
AU  - Kijewski, Marie Foley
AU  - Bianchi, Giada
AU  - Ruberg, Frederick L.
AU  - Di Carli, Marcelo F.
AU  - Liao, Ronglih
AU  - Kwong, Raymond Y.
AU  - Falk, Rodney H.
AU  - Dorbala, Sharmila
TI  - Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain Amyloidosis
AID  - 10.1101/2023.10.04.23296572
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.04.23296572
4099  - http://medrxiv.org/content/early/2023/10/05/2023.10.04.23296572.short
4100  - http://medrxiv.org/content/early/2023/10/05/2023.10.04.23296572.full
AB  - Aims In systemic light-chain (AL) amyloidosis, cardiac involvement portends poor prognosis. Using myocardial characteristics on magnetic resonance imaging (MRI), this study aimed to detect early myocardial alterations, to analyze temporal changes with plasma cell therapy, and to predict risk of major adverse cardiac events (MACE) in AL amyloidosis.Methods and Results Participants with recently diagnosed AL amyloidosis were prospectively enrolled. Presence of AL cardiomyopathy (AL-CMP vs. AL-non-CMP) was determined by abnormal cardiac biomarkers. MRI was performed at baseline and 6 months, with 12-month imaging in AL-CMP cohort. MACE was defined as all-cause death, heart failure hospitalization, or cardiac transplantation. Mayo AL stage was based on troponin T, NT-proBNP, and difference in free light chains. The study cohort included 80 participants (median age 62 years, 58% males). Median left ventricular extracellular volume (ECV) was significantly higher in AL-CMP (53% vs. 30%, p<0.001). ECV was abnormal (>32%) in all AL-CMP and in 47% of AL-non-CMP. ECV tended to increase at 6 months and decreased significantly from 6 to 12 months in AL-CMP (median -3%, p=0.011). ECV was strongly associated with MACE (p<0.001), and improved MACE prediction when added to Mayo AL stage (p=0.002). ECV≤32% identified a cohort without MACE, while ECV>48% identified a cohort with 74% MACE.Conclusions In AL amyloidosis, ECV detects subclinical cardiomyopathy. ECV tends to increase from baseline to 6 months and decreases significantly from 6 and 12 months of plasma cell therapy in AL-CMP. ECV provides excellent risk stratification and offers additional prognostic performance over Mayo AL stage.Competing Interest StatementClerc: Research fellowship from the International Society of Amyloidosis and Pfizer. Cuddy: Investigator-initiated research grant from Pfizer. Ruberg: Consulting fees from Astra Zeneca, research support from Pfizer, Alnylam, and Ionis/Akcea. DiCarli: Research grant from Spectrum Dynamics and Gilead, consulting fees from Sanofi and General Electric. Kwong: Grant funding from Alynlam Pharmaceuticals. Falk: Consulting fees from Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Caelum Biosciences, research funding from GlaxoSmithKline and Akcea. Dorbala: Consulting fees from Pfizer, GE Health Care, Astra Zeneca, Novo Nordisk, investigator-initiated grant from Pfizer, GE Healthcare, Attralus, Siemens, Philips. The other authors do not have any conflicts of interest to declare.Funding StatementThis work was supported by the National Institutes of Health. Dorbala: R01 HL 130563; K24 HL 157648; AHA16 CSA 2888 0004; AHA19SRG34950011 Falk: R01 HL 130563 Liao: AHA16 CSA 2888 0004; AHA19SRG34950011 Ruberg: R01 HL 130563; R01 HL 093148Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mass General Brigham Human Research Committee (NCT02641145).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.